Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Pomalidomide
Drug ID BADD_D01798
Description Pomalidomide, an analogue of thalidomide, is an immunomodulatory antineoplastic agent. FDA approved on February 8, 2013.
Indications and Usage Pomalidomide is indicated for patients with multiple myeloma who have received at least two prior therapies including lenalidomide and bortezomib and have demonstrated disease progression on or within 60 days of completion of the last therapy.
Marketing Status approved
ATC Code L04AX06
DrugBank ID DB08910
KEGG ID D08976
MeSH ID C467566
PubChem ID 134780
TTD Drug ID D0A3ZU
NDC Product Code 65015-893; 17337-0068; 63069-404; 68554-0092; 70225-1106; 59572-501; 59572-502; 55111-989; 68554-0091; 82245-0108; 63069-402; 42973-232; 54893-0038; 59572-503; 59572-504; 63069-403
UNII D2UX06XLB5
Synonyms pomalidomide | CC-4047 | CC 4047 | CC4047 | Imnovid | Pomalyst | actimid
Chemical Information
Molecular Formula C13H11N3O4
CAS Registry Number 19171-19-8
SMILES C1CC(=O)NC(=O)C1N2C(=O)C3=C(C2=O)C(=CC=C3)N
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Influenza like illness08.01.03.0100.012417%
Ingrowing nail23.02.05.0110.001061%Not Available
Insomnia19.02.01.002; 17.15.03.002--
Interstitial lung disease22.01.02.003; 10.02.01.033--Not Available
Iron deficiency14.13.02.0020.001350%Not Available
Joint swelling15.01.02.0040.067584%Not Available
Kaposi's sarcoma16.33.02.001; 11.05.17.0010.000651%Not Available
Left ventricular failure02.05.02.0010.000362%Not Available
Leukopenia01.02.02.001--Not Available
Listless19.04.04.003; 08.01.01.0120.001591%Not Available
Livedo reticularis24.03.04.003; 23.06.05.0010.000530%Not Available
Loss of consciousness17.02.04.004--Not Available
Lung consolidation22.01.02.0100.000241%Not Available
Lung disorder22.02.07.0010.008993%Not Available
Lymphocyte count decreased13.01.06.006--
Lymphoedema24.09.01.001; 01.09.01.0060.001181%
Lymphopenia01.02.02.002--Not Available
Malaise08.01.01.0030.131045%
Marasmus14.03.02.0130.000603%Not Available
Mass08.03.05.0030.002532%Not Available
Memory impairment19.20.01.003; 17.03.02.0030.045860%
Micturition disorder20.02.02.0050.000651%Not Available
Miliaria23.02.03.0140.000820%Not Available
Monoplegia17.01.04.0030.000603%Not Available
Mucous stools07.01.03.0060.000820%Not Available
Multiple allergies10.01.03.0300.008029%Not Available
Muscle spasms15.05.03.0040.119809%
Muscular weakness17.05.03.005; 15.05.06.0010.027632%
Musculoskeletal pain15.03.04.007--
Myocardial infarction24.04.04.009; 02.02.02.007--
The 6th Page    First    Pre   6 7 8 9 10    Next   Last    Total 16 Pages